Ultragenyx to Present at Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Piper Jaffray Raises Price Target on Ultragenyx Pharma (RARE) to $82; Reiterates Overweight
August 9, 2016 8:53 AM EDTPiper Jaffray reiterated an Overweight rating on Ultragenyx Pharma (NASDAQ: RARE), and raised the price target to $82.00 (from $70.00), following the company's 2Q earnings report.
Analyst Steven Breazzano commented, "After the close, RARE reported 2Q earnings and provided an... More
